Ipsapirone

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ipsapirone ( , , ; developmental code names BAY Q 7821 and TVX Q 7821) is a selective 5-HT 1A receptor partial agonist of the arylpiperazine and azapirone families which was under development for the treatment of major depressive disorder and anxiety disorders but was never marketed. It is taken orally. The drug produces antidepressant-like, anxiolytic-like, and antiaggressive effects in rodents. It has been found to increase oxytocin levels in rodents, whereas findings in humans have been mixed. Ipsapirone produces adverse effects including vertigo, dizziness, and dysphoria in humans. Ipsapirone produces 1-(2-pyrimidinyl)piperazine (1-PP), a potent α 2 -adrenergic receptor antagonist, as an active metabolite. However, whereas 1-PP levels with buspirone are 8-fold higher than levels of buspirone itself, 1-PP is only a minor metabolite of ipsapirone constituting 2% of its exposure. Ipsapirone was first described in the scientific literature by 1984. It was developed by Bayer. The drug reached phase 3 clinical trials for treatment of major depressive disorder prior to the discontinuation of its development in 1997. It was also studied for treatment of generalized anxiety disorder.

Ipsapirone ( , , ; developmental code names BAY Q 7821 and TVX Q 7821) is a selective 5-HT 1A receptor partial agonist of the arylpiperazine and azapirone families which was under development for the treatment of major depressive disorder and anxiety disorders but was never marketed. It is taken orally. The drug produces antidepressant-like, anxiolytic-like, and antiaggressive effects in rodents. It has been found to increase oxytocin levels in rodents, whereas findings in humans have been mixed. Ipsapirone produces adverse effects including vertigo, dizziness, and dysphoria in humans. Ipsapirone produces 1-(2-pyrimidinyl)piperazine (1-PP), a potent α 2 -adrenergic receptor antagonist, as an active metabolite. However, whereas 1-PP levels with buspirone are 8-fold higher than levels of buspirone itself, 1-PP is only a minor metabolite of ipsapirone constituting 2% of its exposure. Ipsapirone was first described in the scientific literature by 1984. It was developed by Bayer. The drug reached phase 3 clinical trials for treatment of major depressive disorder prior to the discontinuation of its development in 1997. It was also studied for treatment of generalized anxiety disorder.

External links

Ipsapirone - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365993029 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.